Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:871-875

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thambyrajah, J.
Right arrow Articles by Townend, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thambyrajah, J.
Right arrow Articles by Townend, J. N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*FOLIC ACID
Related Collections
Right arrow Pathophysiology
Right arrow Risk Factors
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2000;102:871.)
© 2000 American Heart Association, Inc.


Clinical Investigation and Reports

Does Folic Acid Decrease Plasma Homocysteine and Improve Endothelial Function in Patients With Predialysis Renal Failure?

J. Thambyrajah, MRCP; M. J. Landray, MRCP; F. J. McGlynn, RGN; H. J. Jones, RGN, BSc; D. C. Wheeler, MD, FRCP; J. N. Townend, MD, MRCP

From the Division of Medical Sciences (Cardiology), University of Birmingham (J.T., M.J.L., H.J.J., J.N.T.), and the Department of Nephrology, Queen Elizabeth Hospital (F.J.M., D.C.W.), Birmingham, UK.

Correspondence to Dr J. Thambyrajah, Department of Cardiovascular Medicine, University Hospital Birmingham NHS Trust, Birmingham B15 2TH, UK. E-mail J.Thambyrajah{at}bham.ac.uk

Background—Considerable evidence suggests that hyperhomocysteinemia is an independent vascular risk factor that promotes atherosclerosis by inducing endothelial dysfunction. Although folic acid reduces hyperhomocysteinemia, the effect on adverse vascular events is unknown. We hypothesized that in patients with chronic renal failure, a condition associated with both hyperhomocysteinemia and atherosclerosis, treatment with folic acid would improve endothelial function.

Methods and Results—In a prospective, double-blind protocol, 100 patients (mean age 62 years, 67 men) with predialysis chronic renal failure were randomized to 5 mg folic acid or placebo daily for 12 weeks. Endothelial function was assessed by measuring (1) endothelium-dependent dilation of the brachial artery, (2) combined serum nitrite/nitrate concentrations, and (3) plasma von Willebrand factor concentration. Baseline characteristics of the 2 groups were similar. At the end of the study, both serum and red cell folate concentrations were greater in the folic acid group than the placebo group [mean (95% CI) 39.0 (29.8 to 51.0) versus 7.7 (6.6 to 8.9) µg/L and 739 (613 to 891) versus 220 (184 to 262) µg/L, respectively; both P<0.001]. Despite a reduction in hyperhomocysteinemia in the folic acid group compared with the placebo group [15.1 (14.1 to 16.2) versus 20.1 (18.2 to 22.2) µmol/L; P<0.001], there were no significant differences in endothelium-dependent dilation, combined serum nitrite/nitrate concentrations, or plasma von Willebrand factor concentration between the 2 groups.

Conclusions—High-dose folic acid lowers but fails to normalize hyperhomocysteinemia in patients with predialysis chronic renal failure. This was not accompanied by an improvement of endothelial function and suggests that treatment with folic acid may not reduce the burden of vascular disease in uremia.


Key Words: atherosclerosis • endothelium • kidney • amino acids




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
I. Baragetti, S. Raselli, A. Stucchi, V. Terraneo, S. Furiani, L. Buzzi, K. Garlaschelli, E. Alberghini, A. L. Catapano, and G. Buccianti
Improvement of endothelial function in uraemic patients on peritoneal dialysis: a possible role for 5-MTHF administration
Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3292 - 3297.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
A. S. Pena, E. Wiltshire, R. Gent, L. Piotto, C. Hirte, and J. Couper
Folic Acid Does Not Improve Endothelial Function in Obese Children and Adolescents
Diabetes Care, August 1, 2007; 30(8): 2122 - 2127.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. J. Anderson, Y.-H. Sun, J. Hubacek, M. E. Hyndman, S. Verma, L. Shewchuk, and N. Scott-Douglas
Effects of folinic acid on forearm blood flow in patients with end-stage renal disease
Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1927 - 1933.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
N. Weiss, N. Ide, T. Abahji, L. Nill, C. Keller, and U. Hoffmann
Aged Garlic Extract Improves Homocysteine-Induced Endothelial Dysfunction in Macro- and Microcirculation
J. Nutr., March 1, 2006; 136(3): 750S - 754S.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
Homocysteine Lowering Trialists' Collaboration
Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials
Am. J. Clinical Nutrition, October 1, 2005; 82(4): 806 - 812.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Fux, D. Kloor, M. Hermes, T. Rock, B. Proksch, A. Grenz, U. Delabar, R. Bucheler, S. Igel, K. Morike, et al.
Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers
Am J Physiol Renal Physiol, October 1, 2005; 289(4): F786 - F792.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
A. Vychytil, M. Fodinger, J. Pleiner, M. Mullner, P. Konner, S. Skoupy, C. Rohrer, M. Wolzt, and G. Sunder-Plassmann
Acute effect of amino acid peritoneal dialysis solution on vascular function
Am. J. Clinical Nutrition, November 1, 2003; 78(5): 1039 - 1045.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
F. Stam, C. van Guldener, C. G. Schalkwijk, P. M. ter Wee, A. J. M. Donker, and C. D. A. Stehouwer
Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity
Nephrol. Dial. Transplant., May 1, 2003; 18(5): 892 - 898.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
R. Vanholder, G. Glorieux, and N. Lameire
Uraemic toxins and cardiovascular disease
Nephrol. Dial. Transplant., March 1, 2003; 18(3): 463 - 466.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
B. Bayes, M. C. Pastor, J. Bonal, J. Junca, J. M. Hernandez, N. Riutort, A. Foraster, and R. Romero
Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients
Nephrol. Dial. Transplant., January 1, 2003; 18(1): 106 - 112.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo
Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia
Vascular Medicine, August 1, 2002; 7(3): 227 - 239.
[Abstract] [PDF]


Home page
Nephrol Dial TransplantHome page
G. Buccianti, S. Raselli, I. Baragetti, F. Bamonti, E. Corghi, C. Novembrino, C. Patrosso, F. M. Maggi, and A. L. Catapano
5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis
Nephrol. Dial. Transplant., May 1, 2002; 17(5): 857 - 864.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M.C. Verhaar, E. Stroes, and T.J. Rabelink
Folates and Cardiovascular Disease
Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 6 - 13.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. N. FRIEDMAN, A. G. BOSTOM, J. SELHUB, A. S. LEVEY, and I. H. ROSENBERG
The Kidney and Homocysteine Metabolism
J. Am. Soc. Nephrol., October 1, 2001; 12(10): 2181 - 2189.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Thambyrajah, M. J. Landray, H. J. Jones, F. J. McGlynn, D. C. Wheeler, and J. N. Townend
A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease
J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1858 - 1863.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
A. A Brown and F. B Hu
Dietary modulation of endothelial function: implications for cardiovascular disease
Am. J. Clinical Nutrition, April 1, 2001; 73(4): 673 - 686.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Bennett-Richards, M. Kattenhorn, A. Donald, G. Oakley, Z. Varghese, L. Rees, and J.E. Deanfield
Does Oral Folic Acid Lower Total Homocysteine Levels and Improve Endothelial Function in Children With Chronic Renal Failure?
Circulation, April 16, 2002; 105(15): 1810 - 1815.
[Abstract] [Full Text] [PDF]